The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Pomalidomide and dexamethasone for R/R AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, outlines the results of a retrospective study analyzing the use of pomalidomide and dexamethasone as therapy for patients with relapsed/refractory (R/R) immunoglobin light-chain (AL) amyloidosis. The study analyzed data from 153 previously treated patients with systemic AL amyloidosis who were treated with 28-day cycles of pomalidomide and dexamethasone. After the completion of six cycles, 44% of patients had obtained at least a partial hematologic response, with 3% achieving complete responses and 23% achieving very good partial responses. Furthermore, hematologic response was associated with improved overall survival and progression-free survival. This interview took place during the 2021 European Myeloma Network (EMN) congress.
